patent.fyi
Applications  /  US 2026/0355219
United States Patent Application Publication

US 2026/0355219 A1

Published
Nov 12, 2026
Filed
Aug 11, 2025
Earliest date on the face
Aug 29, 2022
Classification
A61K 31/57
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.2Single extended release dose

What ifWhat if the regimen consisted of a single administration of an extended-release oral tablet?
Claim language“a plurality of doses”

A hydrophilic polymer matrix hydrates in gastrointestinal fluid and controls drug release through diffusion and erosion. The release profile distributes delivery over several hours after the tablet is swallowed.

1.4Metered oral lipid solution

What ifWhat if each dose consisted entirely of a measured oral liquid?
Claim language“at least one SODF”

A medium-chain triglyceride and surfactant vehicle carries dissolved allopregnanolone and disperses it into droplets when mixed with gastrointestinal fluid. A calibrated oral syringe measures the volume from the formulation concentration and the required drug mass.

1.5One hundred milligram days

What ifWhat if the regimen delivered a fixed total of 100 mg of allopregnanolone each day?
Claim language“from about 200 mg to about 2000 mg”

One tablet supplies the full daily amount at a scheduled administration. Serial plasma samples characterize exposure, and a symptom scale tracks clinical response during the regimen.

1.6Lower fed peak exposure

What ifWhat if the regimen targeted a fed-state peak below 4 ng/mL and used total exposure to assess delivery?
Claim language“a Cmax of at least 4 ng/mL”

A polymer-coated multiparticulate formulation meters release over several hours to limit the early rise in plasma concentration. Serial samples collected after a standardized meal establish the observed peak and the area under the concentration-time curve.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Oral dosing in veterinary pharmacokinetic studies

A veterinary pharmacokinetic study uses solid oral allopregnanolone units in a repeated-dose regimen with species-specific dose levels. Study staff record administration, feeding, and blood collection times for each animal. A laboratory measures plasma allopregnanolone by liquid chromatography coupled to tandem mass spectrometry and reports the highest observed concentration for each sampling interval.

Component substitution

Hard capsules with compressed drug minitablets

A hard hydroxypropyl methylcellulose capsule filled with compressed allopregnanolone minitablets replaces a single compressed tablet. Each minitablet contains a fixed amount of allopregnanolone, and the capsule fill count determines the total drug content per unit. After ingestion, the capsule shell opens and the minitablets disperse in gastrointestinal fluid.

Parameter or scale variation

Unequal doses across two daily administrations

A solid oral unit contains 200 mg of allopregnanolone. A repeated twice-daily regimen assigns one unit at 08:00 and two units at 20:00, for 600 mg per day. Plasma samples collected after each administration provide separate observed morning and evening peak concentrations.

Four equal doses during waking hours

A solid oral unit contains 150 mg of allopregnanolone. A repeated regimen assigns one unit at 07:00, 12:00, 17:00, and 22:00, for 600 mg per day. The schedule creates three 5-hour daytime intervals and one 9-hour overnight interval.

Combination with existing systems

Time-labeled blister cards with electronic administration records

A calendar blister card holds solid oral allopregnanolone units in cavities labeled by day and administration time. A barcode on each card encodes a package identifier that links to the scheduled regimen in an electronic medication administration record. At each administration, staff scan the card and record the number of units given and the actual administration time.

Automated or data-driven variant

Automated peak concentration reporting by meal status

Software imports dose timestamps, meal timestamps, sample collection timestamps, and plasma allopregnanolone concentrations. It assigns each sample to the interval following the most recent recorded administration and classifies each interval using a configured meal-timing rule. For each interval, it reports the highest measured concentration and its elapsed time from administration, with separate summaries for fed and fasted intervals.

Specific version of a part

Fifty milligram tablet units

A tablet press compresses a blend of micronized allopregnanolone, microcrystalline cellulose, and a disintegrant into 50 mg units. Four tablets supply 200 mg at one administration.

Two hundred milligram capsule

A hard capsule contains 200 mg of micronized allopregnanolone blended with microcrystalline cellulose and a wetting agent. The shell dissolves after swallowing and releases the powder into gastrointestinal fluid.

Twice daily scheduled dosing

A blister card groups each day's doses into morning and evening compartments. The subject takes the two doses approximately 12 hours apart.

Two tablets per dose

A unit-dose blister holds two tablets, each containing 100 mg of allopregnanolone. The subject swallows both tablets at the same administration to receive 200 mg.

Fasted peak concentration measurement

The subject takes the solid oral dose after an overnight fast, and serial plasma samples span the expected time of peak concentration. Liquid chromatography coupled with tandem mass spectrometry quantifies allopregnanolone, and the highest measured concentration is compared with 9 ng/mL.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2010/0105646 A1
Published
Apr 29, 2010
Filed
Jun 11, 2008
Class
A61K 31/56
Document BUS 10,940,156 B2
Published
Mar 9, 2021
Filed
Dec 18, 2019
Class
A61K 31/57
Claim 1
Document A
Document B
1.1wherein said PC comprises allopregnanolone in an amount of from about 100 mg to about 500 mg, and
Generally, the total daily dosage will be at least about 10 mg and more preferably at least about 50 mg, and preferably not more than 500 mg per day, administered orally. Capsules or tablets for oral delivery can contain up to a full daily oral dose, e.g., 100 mg or more.
A · US 2010/0105646 A1 · ¶ 86
1.2wherein said administration comprises a dosing regimen, said dosing regimen comprising a plurality of doses, and
The compositions can be administered in a single dose or multiple doses.
A · US 2010/0105646 A1 · ¶ 12
In some embodiments, the method includes a course of treatment with multiple dosages or cycles of treatment (e.g., a first dose or cycle of treatment is a parenteral dose such as an i.v. dose, and a second dose or cycle of treatment is an oral dose).
B · US 10,940,156 B2 · ¶ 23
1.3wherein said dosing regimen comprises a dosing frequency of at least one of QD, BID, TID, and more than TID, and
With oral dosing, one to five and especially two to four and typically three oral doses per day are representative regimens.
B · US 10,940,156 B2 · ¶ 297
1.4wherein said dose comprises at least one SODF, and
Preferably, these formulations are employed in solid dosage forms suitable for simple, and preferably oral, administration of precise dosages. Solid dosage forms for oral administration include, but are not limited to, tablets, soft or hard gelatin or non-gelatin capsules, and caplets.
A · US 2010/0105646 A1 · ¶ 48
The term “unit dosage forms” refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include prefilled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions.
B · US 10,940,156 B2 · ¶ 296
1.5wherein said regimen comprises a minimum daily allopregnanolone administration of from about 200 mg to about 2000 mg, and
Generally, the total daily dosage will be at least about 10 mg and more preferably at least about 50 mg, and preferably not more than 500 mg per day, administered orally.
A · US 2010/0105646 A1 · ¶ 86
In an aspect, provided is a method for treating or preventing a disorder described herein, comprising orally administering a total daily dose of Compound 9, or pharmaceutically acceptable salt or isotopologue thereof, or pharmaceutical composition thereof of about 10 mg to about 100 mg to a subject in need thereof.
B · US 10,940,156 B2 · ¶ 94
1.6wherein said administration of said PC to said subject results in at least one of a Cmax of at least 4 ng/mL of allopregnanolone in said subject when said subject is in a fed state, and a Cmax of at least 9 ng/mL of allopregnanolone in said subject when said subject is in a fasted state.

An empty cell means only that no passage was reproduced there.

Statements in these documents
This invention is in the field of pharmaceutical compositions for enhancing neurological function and methods of use thereof, particularly compositions containing allopregnanolone or a derivative or analogue thereof.
A · US 2010/0105646 A1 · ¶ 2
Accordingly, there is a need for new treatment modalities directed to improving the adverse neurological conditions associated with neuropathies, neurological injuries and age-related neurological decline or impairment.
A · US 2010/0105646 A1 · ¶ 8
There is increasing evidence to support the use of neuroactive steroids, e.g., a neuroactive steroid as described herein, e.g., progesterone and its metabolites; in the treatment and prevention of tremor (e.g., essential tremor), depression (e.g., postpartum depression, major depressive disorder), and anxiety disorder.
B · US 10,940,156 B2 · ¶ 5
In some embodiments, the neuroactive steroid is formulated for parenteral delivery (e.g., intravenous delivery (IV)).
B · US 10,940,156 B2 · ¶ 6
Cite aspatent.fyi, US 2026/0355219 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355219/, SHA-256 f8f284fb0db87ca994821dde395548a21a680d8d03d6206812a9d72c1c165763
First published
Permanent addresshttps://patent.fyi/US20260355219/
Content fingerprint (SHA-256)f8f284fb0db87ca994821dde395548a21a680d8d03d6206812a9d72c1c165763
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi